NCT05592015 2026-02-10
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06530576 2025-11-18
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06716658 2025-11-18
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06530550 2025-08-12
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05941156 2023-07-12
Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Recruiting